Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma

Amar Safdar*, M. Alma Rodriguez, Luis E. Fayad, Gilhen H. Rodriguez, Barbara Pro, Michael Wang, Jorge E. Romaguera, Andre H. Goy, Fredrick B. Hagemeister, Peter McLaughlin, Gerald P. Bodey, Larry W. Kwak, Issam I. Raad, Robert B. Couch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 μg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 μg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 μg and 60% given 135 μg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135-μg vaccine.

Original languageEnglish (US)
Pages (from-to)1394-1397
Number of pages4
JournalJournal of Infectious Diseases
Volume194
Issue number10
DOIs
StatePublished - Nov 15 2006

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma'. Together they form a unique fingerprint.

Cite this